{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:23:23Z","timestamp":1784129003245,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2024XY070"],"award-info":[{"award-number":["2024XY070"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2024XY067"],"award-info":[{"award-number":["2024XY067"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bioorg.2025.109161","type":"journal-article","created":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:52:26Z","timestamp":1761519146000},"page":"109161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Research progress of direct and indirect KRAS-targeting protein degraders in KRAS-mutant cancers"],"prefix":"10.1016","volume":"166","author":[{"given":"Lili","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinkai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayong","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yefei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109161_bb0005","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109161_bb0010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/304507a0","article-title":"Activation of ki-ras2 gene in human colon and lung carcinomas by two different point mutations","volume":"304","author":"Capon","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109161_bb0015","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1073\/pnas.79.11.3637","article-title":"Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses","volume":"79","author":"Der","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2025.109161_bb0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/298343a0","article-title":"T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes","volume":"298","author":"Santos","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109161_bb0025","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/300762a0","article-title":"Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change","volume":"300","author":"Taparowsky","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109161_bb0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/349117a0","article-title":"The GTPase superfamily: conserved structure and molecular mechanism","volume":"349","author":"Bourne","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109161_bb0035","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.chembiol.2017.08.025","article-title":"Ras binder induces a modified switch-II pocket in GTP and GDP states","volume":"24","author":"Gentile","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109161_bb0040","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.109161_bb0045","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-13-1762","article-title":"A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer","volume":"20","author":"Vasan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109161_bb0050","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0092-8674(90)90024-9","article-title":"The neurofibromatosis type 1 gene encodes a protein related to GAP","volume":"62","author":"Xu","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.109161_bb0055","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","article-title":"Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition","volume":"577","author":"Xue","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109161_bb0060","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1128\/MMBR.00031-10","article-title":"Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases","volume":"75","author":"Cargnello","year":"2011","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.bioorg.2025.109161_bb0065","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031492","article-title":"Targeting the MAPK pathway in RAS mutant cancers","volume":"8","author":"Hymowitz","year":"2018","journal-title":"Cold Spring Harbor Perspect. Med."},{"key":"10.1016\/j.bioorg.2025.109161_bb0070","article-title":"Targeting the \u201cundruggable\u201d RAS with biologics","volume":"153","author":"Whaby","year":"2022","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109161_bb0075","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.chembiol.2010.05.011","article-title":"Targeting the undruggable proteome: the small molecules of my dreams","volume":"17","author":"Crews","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109161_bb0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-biochem-061516-044859","article-title":"The ubiquitin system, autophagy, and regulated protein degradation","volume":"86","author":"Varshavsky","year":"2017","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bioorg.2025.109161_bb0085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2025.109161_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810328","article-title":"Recent advances in PROTACs for drug targeted protein research","volume":"23","author":"Yao","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109161_bb0095","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109161_bb0100","article-title":"Targeting KRAS G12C mutations in colorectal cancer","volume":"11","author":"Zhao","year":"2023","journal-title":"Gastroenterol. Rep."},{"key":"10.1016\/j.bioorg.2025.109161_bb0105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/oncolo\/oyad051","article-title":"Practical guidance for the Management of Adverse Events in patients with KRASG12C-mutated non-small cell lung Cancer receiving Adagrasib","volume":"28","author":"Zhang","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2025.109161_bb0110","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1358\/dot.2022.58.4.3400573","article-title":"Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation","volume":"58","author":"Zheng","year":"2022","journal-title":"Drugs Today"},{"key":"10.1016\/j.bioorg.2025.109161_bb0115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-022-01629-2","article-title":"Targeting KRAS mutant cancers: from druggable therapy to drug resistance","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2025.109161_bb0120","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","article-title":"Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung Cancer","volume":"26","author":"Adachi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109161_bb0125","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS(G12C) inhibition in Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"NEW ENGL. J MED."},{"key":"10.1016\/j.bioorg.2025.109161_bb0130","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jtho.2021.04.015","article-title":"KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, Sotorasib and Adagrasib, and overcoming strategies: insights from in vitro experiments","volume":"16","author":"Koga","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2025.109161_bb0135","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","article-title":"Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor","volume":"172","author":"Janes","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.109161_bb0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.chembiol.2019.12.006","article-title":"Exploring targeted degradation strategy for oncogenic KRASG12C","volume":"27","author":"Zeng","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109161_bb0145","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/17476348.2023.2265810","article-title":"Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics","volume":"17","author":"Zhang","year":"2023","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.bioorg.2025.109161_bb0150","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRAS(G12C) by VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bioorg.2025.109161_bb0155","first-page":"19","article-title":"Exploring targeted degradation strategy for oncogenic KRASG12C","volume":"16","author":"Gray","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109161_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105447","article-title":"Discovery of KRAS G12C-IN-3 and pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity","volume":"117","author":"Li","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109161_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114088","article-title":"Efficient targeted oncogenic KRAS(G12C) degradation via first reversible-covalent PROTAC","volume":"230","author":"Yang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109161_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115857","article-title":"Discovery of highly potent and selective KRAS(G12C) degraders by VHL-recruiting PROTACs for the treatment of tumors with KRAS(G12C)-mutation","volume":"261","author":"Yang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109161_bb0175","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s42004-025-01662-4","article-title":"Discovery of KRAS(G12D) selective degrader ASP3082","volume":"8","author":"Yoshinari","year":"2025","journal-title":"Commun. Chem."},{"key":"10.1016\/j.bioorg.2025.109161_bb0180","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/acs.jmedchem.3c01622","article-title":"Design, synthesis, and biological evaluation of potent and selective PROTAC degraders of oncogenic KRAS(G12D)","volume":"67","author":"Zhou","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109161_bb0185","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.adm8684","article-title":"Targeting cancer with small-molecule pan-KRAS degraders","volume":"385","author":"Popow","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2025.109161_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccell.2025.07.006","article-title":"A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers","volume":"43","author":"Feng","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2025.109161_bb0195","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","article-title":"BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition","volume":"11","author":"Hofmann","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.109161_bb0200","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature13713","article-title":"Discovery and characterization of small molecules that target the GTPase Ral","volume":"515","author":"Yan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109161_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101230","article-title":"Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells","volume":"14","author":"Plangger","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bioorg.2025.109161_bb0210","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12672-022-00550-w","article-title":"Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines","volume":"13","author":"Plangger","year":"2022","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bioorg.2025.109161_bb0215","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1021\/acs.jmedchem.3c02140","article-title":"Discovery of five SOS2 fragment hits with binding modes determined by SOS2 X-ray Cocrystallography","volume":"67","author":"Smith","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109161_bb0220","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1021\/acs.jmedchem.1c01774","article-title":"Discovery of the first-in-class agonist-based SOS1 PROTACs effective in human Cancer cells Harboring various KRAS mutations","volume":"65","author":"Zhou","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109161_bb0225","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1021\/acs.jmedchem.3c00075","article-title":"Discovery of a potent, cooperative, and selective SOS1 PROTAC ZZ151 with in vivo antitumor efficacy in KRAS-mutant cancers","volume":"66","author":"Zhou","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109161_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112868","article-title":"FAK-targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer","volume":"408","author":"Liu","year":"2021","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bioorg.2025.109161_bb0235","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.2174\/1568026619666190828160804","article-title":"Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations in the occurrence and treatment of pancreatic Cancer","volume":"19","author":"Zhu","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109161_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212455","article-title":"Targeting PI3K\/Akt\/mTOR pathway by different flavonoids: a Cancer Chemopreventive approach","volume":"22","author":"Zughaibi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109161_bb0245","doi-asserted-by":"crossref","first-page":"7482","DOI":"10.1038\/sj.onc.1209088","article-title":"The Akt\/PKB pathway: molecular target for cancer drug discovery","volume":"24","author":"Cheng","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2025.109161_bb0250","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/AKT pathway for cancer drug discovery","volume":"4","author":"Hennessy","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.109161_bb0255","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.109161_bb0260","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2025.109161_bb0265","doi-asserted-by":"crossref","first-page":"14237","DOI":"10.1021\/acs.jmedchem.2c01454","article-title":"Novel allosteric inhibitor-derived AKT proteolysis targeting chimeras (PROTACs) enable potent and selective AKT degradation in KRAS\/BRAF mutant cells","volume":"65","author":"Yu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109161_bb0270","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825010417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825010417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:31:31Z","timestamp":1778661091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825010417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":54,"alternative-id":["S0045206825010417"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109161","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress of direct and indirect KRAS-targeting protein degraders in KRAS-mutant cancers","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109161"}}